Immunotherapy, Adoptive

• 

  Subject Areas on Research

  • 18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer. 30 October-2 November 2003, Bethesda, Maryland, USA. 
  • A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model. 
  • A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. 
  • A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors. 
  • Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma. 
  • Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. 
  • Adoptive immunotherapy for malignant glioma. 
  • Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. 
  • Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. 
  • Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. 
  • Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. 
  • Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. 
  • Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. 
  • B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. 
  • B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. 
  • BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT. 
  • CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains. 
  • Characterization of tumor-specific cytotoxic effector cells with a novel CD3-/Thy-1+ phenotype. 
  • Chasing cancer with chimeric antigen receptor therapy. 
  • Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. 
  • Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy. 
  • Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy. 
  • Circulating CD8+CD28- suppressor T cells tied to poorer prognosis among metastatic breast cancer patients receiving adoptive T-cell therapy: A cohort study. 
  • Clinical immunotherapy for brain tumors. 
  • Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS). 
  • Current status of adoptive immunotherapy of malignancies. 
  • Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. 
  • Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. 
  • Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. 
  • Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. 
  • Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. 
  • Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. 
  • Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease. 
  • Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. 
  • Driving an improved CAR for cancer immunotherapy. 
  • Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. 
  • Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. 
  • Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma. 
  • Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. 
  • Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs. 
  • Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7. Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation. 
  • Experimental trials of immunotherapy for malignant melanoma. 
  • Facultative role of germinal centers and T cells in the somatic diversification of IgVH genes. 
  • Flow cytometric detection of lymphocyte proliferation in eyes with immunogenic inflammation. 
  • Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. 
  • Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines. 
  • Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. 
  • Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care. 
  • Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. 
  • Generation of tumor-specific T lymphocytes for the treatment of posttransplant lymphoma. 
  • Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. 
  • Graft-versus-host reactions: anti-leukemia effects of donor T cells. 
  • Highlights from the 46 th annual meeting of the American Society of Hematology. 
  • Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. 
  • Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. 
  • Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation. 
  • Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases. 
  • Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells. 
  • IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer. 
  • Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40. 
  • Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors. 
  • Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. 
  • Immunoregulatory T cells in cancer immunotherapy. 
  • Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow. 
  • Immunotherapy and monoclonal antibody therapies. 
  • Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. 
  • Immunotherapy of malignant brain tumors. 
  • Immunotherapy of surgical malignancies. 
  • Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. 
  • Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells. 
  • Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. 
  • Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy. 
  • Induction of protective CTL responses in newborn mice by a murine retrovirus. 
  • Induction of specific tolerance by intrathymic injection of recipient muscle cells transfected with donor class I major histocompatibility complex. 
  • Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. 
  • Interferon gamma enhances lymphokine-activated killer cell adhesion but not lysis of head and neck squamous cell carcinoma. 
  • Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation. 
  • In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia. 
  • In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. 
  • Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses. 
  • Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. 
  • MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. 
  • Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. 
  • Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy. 
  • Non-pharmacologic approaches to graft-versus-host prevention. 
  • Ordinary Differential Equation Models for Adoptive Immunotherapy. 
  • Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. 
  • Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. 
  • Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. 
  • Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. 
  • Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. 
  • Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. 
  • Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors. 
  • Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. 
  • Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45). 
  • Prospects for cellular immunotherapy for metastatic melanoma. 
  • Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma. 
  • Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. 
  • Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells. 
  • Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. 
  • Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. 
  • Selective modification of antigen-specific T cells by RNA electroporation. 
  • Sickle erythrocytes target cytotoxics to hypoxic tumor microvessels and potentiate a tumoricidal response. 
  • Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. 
  • Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. 
  • Suppression of hepatic allograft rejection in the rat by mitomycin C-treated donor splenocytes: analysis of the immune status. 
  • Synergy between tumor immunotherapy and antiangiogenic therapy. 
  • Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. 
  • Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response. 
  • The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion. 
  • The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. 
  • Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience. 
  • Toll-like receptors in tumor immunotherapy. 
  • Toward effective immunotherapy for the treatment of malignant brain tumors. 
  • Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. 
  • Treatment of human melanoma hepatic metastases in nude mice with human cytotoxic T lymphocytes. 
  • Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity. 
  • Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. 
  • Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. 
  • Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. 
  • Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. 
  • Type 17 CD8+ T cells display enhanced antitumor immunity. 
  • Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. 
  • Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. 
  • WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy. 
  • [Adjuvant therapy of surgically removed stage I melanoma]. 
  • gammadelta T cells: a new frontier for immunotherapy? 
• 

  Keywords of People

  • Inman, Brant Allen, Cary N. Robertson, MD, Associate Professor, Surgery, Urology
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology